These results further support the notion that phenotypically indistinguishable A549 TIS cancer cell populations, at least in terms of positive SA-β-gal staining, exhibit a marked variability in their senolytic response to BCL-XL-targeting versus BCL2-/MCL-1-specific BH3 mimetics (Fig. 2, bottom panel). The gene discussed is BCL2; the disease is cancer.